New diabetes shot GZR18 takes on semaglutide in major trial

NCT ID NCT06778967

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests a new injectable drug called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by metformin or other oral medications. Participants receive either GZR18 or the approved drug semaglutide to compare how well each lowers blood sugar and affects weight. The goal is to see if GZR18 is a safe and effective new treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GZR18 injection (a drug similar to semaglutide, given as a shot under the skin)
What this could lead to
If it works, this could offer a new once-weekly injection option to help people with type 2 diabetes lower blood sugar and possibly lose weight.
What could go wrong
This is a phase 3 trial, but it only includes Chinese participants, so results may not apply to other groups. GZR18 is new and may cause side effects like nausea or vomiting, common with this class of drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.